Welcome to our dedicated page for Parkervision SEC filings (Ticker: PRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for ParkerVision, Inc. (PRKR), a Florida corporation focused on radio-frequency (RF) technologies for advanced wireless communication systems. Through its periodic and current reports, ParkerVision provides detailed information on its operations, financial condition, litigation posture, and capital-raising activities.
Investors can use ParkerVision’s annual reports on Form 10-K and quarterly reports on Form 10-Q to review its RF technology and licensing focus, operating expenses, net losses, contingent payment obligations, and cash flows. These filings also include risk factor discussions that the company references in its press releases, covering topics such as outcomes of patent litigation, interpretations of patent law and claim scope, decisions by the Patent Trial and Appeal Board (PTAB), and market conditions affecting financing.
Current reports on Form 8-K are particularly important for tracking material events. Recent 8-K filings describe registered direct offerings of common stock under ParkerVision’s effective shelf registration statement on Form S-3, including sales to accredited investors and to a director. These filings outline subscription agreements, offering prices, aggregate purchase amounts, and legal opinions regarding the issuance of securities. Other 8-Ks furnish earnings press releases that summarize quarterly and year-to-date financial results and provide context for changes in operating expenses and contingent payment obligations.
Through this filings page, users can access ParkerVision’s real-time updates as they are filed with EDGAR, including 10-K, 10-Q, and 8-K reports, as well as registration statements and prospectus supplements related to its shelf registration. AI-powered tools on the platform can help summarize lengthy filings, highlight key sections such as litigation disclosures, capital structure changes, and risk factors, and make it easier to interpret complex legal and financial language without replacing the full primary documents.
ParkerVision, Inc. reported a 2025 net loss of $7.4M, an improvement from a $14.5M loss in 2024, mainly due to a $0.6M gain from revaluing contingent payment obligations versus a $9.6M loss in 2024. Licensing revenue remained at zero and selling, general and administrative expenses rose to $7.6M from $4.3M, driven partly by a $3.0M increase in share-based compensation, including a one-time $2.5M noncash option modification charge.
Cash and cash equivalents were $4.4M at December 31, 2025, with net cash used in operations of $5.1M. The company raised approximately $4.5M in November 2025 through a registered direct sale of 21.2M shares at $0.21 per share and in March 2026 issued 3.2M shares at $0.21 per share to settle $0.67M of upcoming convertible note maturities.
On the legal front, the Court of Appeals for the Federal Circuit granted an expedited schedule in the Qualcomm appeal, with briefing completed by March 23, 2026 and oral argument to follow. A planned jury trial against MediaTek in Waco, Texas was postponed after the judge requested further support for the company’s damages expert, with a new schedule to be set after updated reports and briefings.
ParkerVision, Inc. filed a prospectus supplement dated March 13, 2026 updating its resale prospectus to register 9,387,500 shares of Common Stock for resale by selling shareholders. The supplement states the company will receive no proceeds from those resales; Option exercises could yield up to $42,620 in gross proceeds.
The supplement incorporates a Form 8-K reporting exchange agreements under which the company issued 3,277,099 shares on March 13, 2026 in exchange for cancellation of convertible notes with aggregate principal of $675,000 plus accrued interest.
ParkerVision filed a Prospectus Supplement registering 16,638,353 shares of Common Stock for resale, representing shares issuable upon conversion of previously disclosed convertible promissory notes at a fixed conversion price of $0.13 per share.
The supplement attaches a Form 8-K reporting that on March 13, 2026 the company completed exchange agreements under Section 3(a)(9), issuing an aggregate of 3,277,099 shares of Common Stock at an exchange price of $0.21 per share to cancel Exchange Notes with aggregate principal of $675,000 and accrued interest of approximately $13,200.
ParkerVision, Inc. filed a Prospectus Supplement registering the resale of 1,578,946 shares of common stock, consisting of 1,052,631 issued shares and 526,315 shares issuable upon exercise of warrants. The selling stockholder will receive proceeds from any resale; the company will not.
The supplement states the Company would receive up to $526,315 if the Warrants are exercised for cash and expects to use any proceeds for general working capital, including payment of litigation expenses. The supplement attaches a Form 8-K reporting that on March 13, 2026 the Company exchanged convertible notes for 3,277,099 shares at an exchange price of $0.21 per share in reliance on Section 3(a)(9), canceling notes with aggregate principal of $675,000 and accrued interest of approximately $13,200.
ParkerVision, Inc. registers 13,342,953 shares of Common Stock for resale under a prospectus supplement dated March 13, 2026. The resale registration covers shares held by selling stockholders and the company states it will not receive proceeds from those resales.
The supplement also attaches a Form 8-K reporting that the company issued an aggregate of 3,277,099 shares on March 13, 2026 in exchange for cancellation of convertible notes with aggregate principal of $675,000 and accrued interest of approximately $13,200 at an exchange price of $0.21 per share, using the Section 3(a)(9) exemption. The prospectus notes the company would receive up to $2,833,756 if certain warrants are exercised for cash.
ParkerVision, Inc. files a prospectus supplement registering 5,871,584 shares of Common Stock for resale by selling stockholders under its Prospectus dated September 2, 2020.
The supplement incorporates a Current Report on Form 8-K dated March 13, 2026, which reports that the company issued an aggregate of 3,277,099 shares of Common Stock on March 13, 2026 in exchange for cancellation of convertible promissory notes with an aggregate outstanding principal amount of $675,000 and accrued interest of approximately $13,200. The company states it will not receive proceeds from the resale of the registered shares.
ParkerVision, Inc. supplements its existing prospectus to register the resale of 16,809,295 shares of Common Stock by selling stockholders. The prospectus supplement explains that the registered shares consist of convertible-note conversions, private placements, shares issued for services and payables, and up to 5,000,000 and 200,000 shares issuable upon exercise of warrants held by Aspire Capital and Tailwinds, respectively.
The company states it will not receive proceeds from the resale by selling stockholders; however, if the Aspire and Tailwinds warrants are exercised for cash, the company would receive up to an aggregate of $3,900,000, which it expects to use for general working capital and corporate purposes. The supplement incorporates a Form 8-K dated March 13, 2026 describing exchange agreements that resulted in issuance of 3,277,099 shares to cancel convertible notes with aggregate principal of $675,000.
ParkerVision, Inc. files a prospectus supplement registering 18,014,164 shares of Common Stock for resale by selling stockholders under its existing prospectus.
The supplement states the registered shares consist of convertible-note conversions, consulting-share issuances and a warrant, and that the company will not receive proceeds from resales by the selling stockholders. The supplement also attaches an 8-K dated March 13, 2026 reporting that the company issued 3,277,099 shares pursuant to exchanges that cancelled convertible notes with aggregate principal of $675,000 plus approximately $13,200 of accrued interest, issued at an exchange price of $0.21 per share.
ParkerVision, Inc. files a prospectus supplement to register 17,189,660 shares of Common Stock for resale by selling stockholders under prior registration statements. The supplement incorporates the Company’s Form 8-K dated March 13, 2026 concerning exchange transactions.
Separately, the Company issued 3,277,099 shares of Common Stock on March 13, 2026, in exchange under Section 3(a)(9) for cancellation of convertible notes with an aggregate principal of $675,000 plus approximately $13,200 of accrued interest at an exchange price of $0.21 per share.
ParkerVision, Inc. registered 12,800,000 shares of Common Stock by prospectus supplement dated March 13, 2026.
The supplement states the 12,800,000 shares consist of up to 7,800,000 shares issuable upon conversion of convertible promissory notes and 5,000,000 shares issuable upon exercise of a five-year warrant. The company will not receive proceeds from selling stockholders; if the warrant is exercised for cash, the company would receive up to $800,000 to fund patent enforcement and working capital.
Separately, the company entered into exchange agreements dated March 13, 2026 to cancel convertible notes: the company issued 3,277,099 shares at an exchange price of $0.21 per share in exchange for cancellation of notes with aggregate principal of $675,000 plus approximately $13,200 of accrued interest.